natgillin/translations-raw huggingface dataset:
Kinzalmono blev sammenlignet med placebo (et virkningsløst præparat) og med andre lægemidler mod forhøjet blodtryk (atenolol, lisinopril, enalapril, amlodipin).
Kinzalmono was compared with placebo (a dummy treatment) and with other medicines for hypertension (atenolol, lisinopril, enalapril and amlodipine).
Det vigtigste mål for virkningen var sænkning af det diastoliske blodtryk (dvs. blodtrykket målt i hvilefasen mellem to hjerteslag.
The main measure of effectiveness was the reduction in diastolic blood pressure (the blood pressure measured between two heartbeats).
Reproduction is authorised provided the source is acknowledged Hvilken fordel viser undersøgelserne, at der er ved Kinzalmono?
What benefit has Kinzalmono shown during the studies?
Kinzalmonos var mere effektivt end placebo til at nedsætte det diastoliske blodtryk, og virkningerne af Kinzalmono modsvarede virkningerne af andre lægemidler mod forhøjet blodtryk.
Kinzalmono was more effective than placebo at reducing diastolic blood pressure and had similar effects to the other medicines for hypertension.
Almindeligvis forekommer der ikke bivirkninger ved Kinzalmono.
Side effects with Kinzalmono are not common.
De følgende bivirkninger optræder hos mellem 1 og 10 patienter ud af 100: hyperkaliæmi (højt indhold af kalium i blodet), besvimelsesanfald, søvnløshed, svimmelhed, hypotension (lavt blodtryk, dyspnø (vanskeligt ved at trække vejret, abdominale smerter (mavepine, diarré, tørhed i munden, dyspepsi (halsbrand), flatulens (luft i maven), hyperhidrose (forøget svedafsondring), kløe, myalgi (muskelsmerter), nyreproblemer, herunder nyresvigt og brystsmerter.
However, the following side effects are seen in between 1 and 10 patients in 1,000: hyperkalaemia (high blood potassium levels), syncope (fainting), insomnia (difficulty sleeping), vertigo (a spinning sensation), hypotension (low blood pressure), dyspnoea (difficulty breathing), abdominal (tummy) pain, diarrhoea, dry mouth, dyspepsia (heartburn), flatulence (gas), hyperhidrosis (excessive sweating), pruritus (itching), myalgia (muscle pain), renal impairment (kidney problems) including renal failure (kidney failure), and chest pain.
Den fuldstændige liste over alle de indberettede bivirkninger ved Kinzalmono fremgår af indlægssedlen.
For the full list of all side effects reported with Kinzalmono, see the Package Leaflet.
Kinzalmono bør ikke anvendes af personer, som kan være overfølsomme (allergiske) over for telmisartan eller et af de øvrige indholdsstoffer.
Kinzalmono should not be used in people who may be hypersensitive (allergic) to telmisartan or any of the other ingredients.
Lægemidlet må ikke anvendes af kvinder, som er over tre måneder henne i graviditeten, eller som ammer.
It must not be used in women who are more than three months pregnant or who are breast-feeding.
Det anbefales ikke at anvende lægemidlet i løbet af de tre første måneder af graviditeten.
Its use during the first three months of pregnancy is not recommended.
Kinzalmono må ikke anvendes af personer, der har alvorlige leverproblemer eller galdeproblemer.
Kinzalmono must not be used in people who have severe liver problems or bile problems.
Udvalget for Humanmedicinske Lægemidler (CHMP) konkluderede, at fordelene ved Kinzalmono er større end risiciene ved behandling af essentiel hypertension hos voksne.
The Committee for Medicinal Products for Human Use (CHMP) decided that Kinzalmono’ s benefits are greater than its risks for the treatment of essential hypertension in adults.
Udvalget anbefalede udstedelse af markedsføringstilladelse for Kinzalmono.
The Committee recommended that Kinzalmono be given marketing authorisation.
Andre oplysninger om Kinzalmono:
Other information about Kinzalmono:
Europa- Kommissionen udstedte en markedsføringstilladelse med gyldighed i hele Den Europæiske Union for Kinzalmono den 16. december 1998.
The European Commission granted a marketing authorisation valid throughout the European Union for Kinzalmono on 16 December 1998.
Markedsføringstilladelsen blev fornyet den 16. december 2003 og den 16. december 2008.
The marketing authorisation was renewed on 16 December 2003 and on 16 December 2008.
Indehaveren af denne markedsføringstilladelse er Bayer Healthcare AG.
The marketing authorisation holder is Bayer Healthcare AG.
Den fuldstændige EPAR for Kinzalmono findes her.
The full EPAR for Kinzalmono is available here.
Dette sammendrag blev sidst ajourført i 12- 2008
This summary was last updated in 12-2008.
Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter Tabletter
Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet Tablet
Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC) Blister (PA/ Alu/ PVC)
blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC) blister (PA/ alu/ PVC)
14 tabletter 28 tabletter 56 tabletter 98 tabletter 14 tabletter 28 tabletter 56 tabletter 98 tabletter 14 tabletter 28 tabletter 56 tabletter 98 tabletter 28 x 1 tabletter 28 x 1 tabletter
14 tablets 28 tablets 56 tablets 98 tablets 14 tablets 28 tablets 56 tablets 98 tablets 14 tablets 28 tablets 56 tablets 98 tablets 28 x 1 tablets 28 x 1 tablets
Hvide runde tabletter, hvori firmaets logo og koden 50H er præget.
White round tablets engraved with the code number '50H 'on one side and the company logo on the other side.
Hydrochlorthiazid har en additiv virkning på telmisartans blodtrykssænkende virkning.
Alternatively, telmisartan may be used in combination with thiazide-type diuretics such as hydrochlorothiazide, which has been shown to have an additive blood pressure lowering effect with telmisartan.
5. 1).
When considering raising the dose, it must be borne in mind that the maximum antihypertensive effect is generally attained four to eight weeks after the start of treatment (see section 5.1).
Telmisartan kan både tages med mad eller alene.
Telmisartan may be taken with or without food.
4. 4.).
A lower starting dose of 20 mg is recommended in these patients (see section 4.4).
4. 4).
In patients with mild to moderate hepatic impairment the posology should not exceed 40 mg once daily (see section 4.4).
Børn Kinzalmono bør ikke anvendes til børn og unge under 18 år på grund af utilstrækkelig dokumentation for sikkerhed og virkning.
Paediatric patients Kinzalmono is not recommended for use in children below 18 years due to a lack of data on safety and efficacy.
• Overfølsomhed over for det aktive stof eller et eller flere af hjælpestofferne (se pkt.
• Hypersensitivity to the active substance or to any of the excipients (see section 6.1)
4. 6) • Obstruktive galdelidelser • Svært nedsat leverfunktion
2 • Second and third trimester of pregnancy (see sections 4.4 and 4.6) • Lactation (see section 4.6) • Biliary obstructive disorders • Severe hepatic impairment
Graviditet Angiotensin II- receptorantagonister bør ikke anvendes under graviditet.
Angiotensin II receptor antagonists should not be initiated during pregnancy.
4. 3), idet telmisartan overvejende udskilles med galden.
Kinzalmono is not to be given to patients with cholestasis, biliary obstructive disorders or severe hepatic impairment (see section 4.3) since telmisartan is mostly eliminated with the bile.
Specielt efter den første dosis af Kinzalmono kan der forekomme symptomatisk hypotension hos patienter, som har for lavt volumen i blodbanen eller natriummangel på grund af kraftig diuretisk behandling, saltfattig diæt, diarré eller opkastning.
Symptomatic hypotension, especially after the first dose of Kinzalmono, may occur in patients who are volume and/ or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhoea, or vomiting.
Volumen - og/ eller natriumdepletering bør korrigeres før behandling med Kinzalmono.
Volume and/ or sodium depletion should be corrected prior to administration of Kinzalmono.
Dobbelt hæmning af renin- angiotensin- aldosteronsystemet:
Dual blockade of the renin-angiotensin-aldosterone system:
Oftest er det set, som en konsekvens af anvendelsen af flere lægemidler, der hæmmer renin - angiotensin- aldosteronsystemet.
As a consequence of inhibiting the renin- angiotensin-aldosterone system, hypotension and changes in renal function (including acute renal failure) have been reported in susceptible individuals, especially if combining medicinal products that affect this system.
Sådan flerstofbehandling bør alene anvendes til individuelt definerede patienter og med tæt monitorering af nyrefunktionen.
Dual blockade of the renin-angiotensin-aldosterone system (e. g. by adding an ACE- inhibitor to an angiotensin II receptor antagonist) is therefore not recommended in patients with already controlled blood pressure and should be limited to individually defined cases with close monitoring of renal function.
4. 8).
In patients whose vascular tone and renal function depend predominantly on the activity of the renin- angiotensin-aldosterone system (e. g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system such as telmisartan has been associated with acute hypotension, hyperazotaemia, oliguria, or rarely acute renal failure (see section 4.8).
3 Aorta - og mitralklapstenose, obstruktiv hypertrofisk kardiomyopati:
3 Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:
Som ved brug af andre vasodilatatorer, bør særlig forsigtighed udvises hos patienter, der lider af aorta - eller mitralklapstenose eller obstruktiv hypertrofisk kardiomyopati.
As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.
Hyperkaliæmi:
Hyperkalaemia:
Medicin, som påvirker renin- angiotensin- aldosteronsystemet, kan forårsage hyperkaliæmi.
The use of medicinal products that affect the renin-angiotensin-aldosterone system may cause hyperkalaemia.
Hyperkaliæmi kan være fatal for ældre, for patienter med nedsat nyreinsufficiens, for diabetespatienter, for patienter i behandling med andre lægemidler, der kan øge kaliumniveauet og/ eller for patienter med tilstødende komplikationer.
In the elderly, in patients with renal insufficiency, in diabetic patients, in patients concomitantly treated with other medicinal products that may increase potassium levels, and/ or in patients with intercurrent events, hyperkalaemia may be fatal.
Før start af behandling med flere typer medicin, der påvirker renin- angiotensin- aldosteronsystemet bør man nøje afveje fordele og ulemper mod hinanden..
Before considering the concomitant use of medicinal products that affect the renin-angiotensin- aldosterone system, the benefit risk ratio should be evaluated.
De væsentlige risikofaktorer, hvor hyperkaliæmi kan forekomme, er: − Diabetes mellitus, nedsat nyrefunktion, alder (> 70 år) − Samtidig anvendelse af lægemidler, der påvirker renin- angiotensin- aldosteronsystemet og/ eller kaliumtilskud.
- Diabetes mellitus, renal impairment, age (> 70 years)
Lægemidler, der kan udløse hyperkaliæmi er kaliumholdige saltsubstitutter, kaliumbesparende diuretika, ACE- hæmmere, angiotensin II- receptorantagonister, non steroide antiinflammatoriske lægemidler (NSAIDs, herunder selektive COX- 2- hæmmere), heparin, immunosuppressiva (cyclosporin eller tacrolimus) og trimethoprim. − Tilstødende komplikationer, især dehydrering, akut hjertedekompensation, metabolsk acidose, forværring af nyrefunktionen, akut forværring af nyrernes tilstand (f. eks. ved infektiøse sygdomme), cellenedbrydning (f. eks. ved akut ekstremitetiskæmi, rabdomyolyse, større traumer).
Medicinal products or therapeutic classes of medicinal products that may provoke hyperkalaemia are salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti-inflammatory medicinal products (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim.
Det anbefales at monitorere serumkalium nøje hos patienter i risikogruppen (se pkt. 4. 5).
Close monitoring of serum potassium in at risk patients is recommended (see section 4.5).
Patienter med sjælden arvelig fruktoseintolerans bør ikke tage Kinzalmono.
Patients with rare hereditary problems of fructose intolerance should not take Kinzalmono.
Etniske forskelle:
Ethnic differences:
Dette skyldes muligvis en hyppigere forekomst af lavt reninniveau i den hypertensive negroide population.
As observed for angiotensin converting enzyme inhibitors, telmisartan and the other angiotensin II receptor antagonists are apparently less effective in lowering blood pressure in black people than in non-blacks, possibly because of higher prevalence of low-renin states in the black hypertensive population.
Som ved andre antihypertensiva, kan en for kraftig reduktion af blodtrykket hos patienter med iskæmisk kardiopati eller iskæmisk kardiovaskulær sygdom resultere i myokardieinfarkt eller apopleksi (slagtilfælde).
As with any antihypertensive agent, excessive reduction of blood pressure in patients with ischaemic cardiopathy or ischaemic cardiovascular disease could result in a myocardial infarction or stroke.
4. 8).
As with others drugs acting on the renin-angiotensin-aldosterone system, telmisartan may provoke hyperkalaemia (see section 4.4).
Kaliumholdige saltsubstitutter, kaliumbesparende diuretika, ACE- hæmmere, angiotensin II- receptorantagonister, non steroide antiinflammatoriske lægemidler (NSAIDs herunder selektive COX- 2- hæmmere), heparin, immunosuppressiva (cyclosporin eller tacrolimus) og trimethoprim.
The risk may increase in case of treatment combination with other medicinal products that may also provoke hyperkalaemia (salt substitutes containing potassium, potassium-sparing diuretics, ACE inhibitors, angiotensin II receptor antagonists, non steroidal anti- inflammatory drugs (NSAIDs, including selective COX-2 inhibitors), heparin, immunosuppressives (cyclosporin or tacrolimus), and trimethoprim).
Risikoen er i særdeleshed høj ved samtidig behandling med kaliumbesparende diuretika, og med kaliumholdige saltsubstitutter.
A
Derimod er kombinationer med ACE- hæmmere eller NSAID mindre risikable, forudsat at de foreskrevne forholdsregler følges.
4 combination with ACE inhibitors or NSAIDs, for example, presents a lesser risk provided that precautions for use are strictly followed.
4 Kaliumbesparende diuretika eller kaliumtilskud:
Potassium sparing diuretics or potassium supplements:
Angotensin II- receptorantagonister, såsom telmisartan, mindsker diuretisk fremkaldt kaliumtab.
Angiotensin II receptor antagonists such as telmisartan, attenuate diuretic induced potassium loss.
Kaliumbesparende diuretika som spironolakton, eplerenon, triamteren eller amilorid, kaliumtilskud eller kaliumholdige saltsubstitutter kan medføre en signifikant stigning i serumkalium.
Potassium sparing diuretics e. g. spirinolactone, eplerenone, triamterene, or amiloride, potassium supplements, or potassium-containing salt substitutes may lead to a significant increase in serum potassium.
I sjældne tilfælde er dette også set ved behandling med angiotensin II- receptorantagonister, herunder telmisartan.
Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors, and with angiotensin II receptor antagonists, including telmisartan.
Hvis denne kombination skønnes nødvendig, tilrådes tæt monitorering af serum- lithiumniveauet.
If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.
Non steroide antiinflammatoriske lægemidler:
Non-steroidal anti-inflammatory medicinal products:
NSAID (f. eks. acetylsalicylsyre) i doser beregnet til antiinflammatorisk behandling, COX- 2- hæmmere og ikke- selektive NSAID) kan muligvis nedsætte den antihypertensive virkning af angiotensin II - receptorantagonister.
NSAIDs (i. e. acetylsalicylic acid at anti-inflammatory dosage regimens, COX-2 inhibitors and non- selective NSAIDs) may reduce the antihypertensive effect of angiotensin II receptor antagonists.
Der kan tillige opstå akut nyresvigt, som i de fleste tilfælde er reversibelt.
In some patients with compromised renal function (e. g. dehydrated patients or elderly patients with compromised renal function), the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible.
I et studie medførte samtidig administration af telmisartan og ramipril en op til 2. 5 gange øgning af AUC0- 24 og Cmax af ramipril og ramiprilat.
In one study the co-administration of telmisartan and ramipril led to an increase of up to 2.5 fold in the AUC0-24 and Cmax of ramipril and ramiprilat.
Vanddrivende (thiazider eller loop diuretika):
Diuretics (thiazide or loop diuretics):
Der kan opstå volumendepletion og risiko for hypotension ved initiering af behandling med telmisartan, hvis patienten forudgående har modtaget behandling med høje doser af diuretika såsom furosemid (loop diuretika) og hydrochlorthiazid (thiazid diuretika),
Prior treatment with high dose diuretics such as furosemide (loop diuretic) and hydrochlorothiazide (thiazide diuretic) may result in volume depletion and in a risk of hypotension when initiating therapy with telmisartan.
Andre antihypertensive lægemidler:
Other antihypertensive agents:
Ud fra de farmakologiske egenskaber må det forventes, at den hypotensive virkning af alle antihypertensiva inklusive telmisartan vil forstærkes af følgende lægemidler:
Based on their pharmacological properties it can be expected that the following medicinal products may potentiate the hypotensive effects of all antihypertensives including telmisartan:
Baclofen, amifostine.
Baclofen, amifostine.
Corticosteroider (systemisk administration):
Corticosteroïds (systemic route):
4. 4.).
5 The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4).
4. 3 og 4. 4):
Pregnancy (see section 4.3 and 4.4):
Der foreligger ikke tilstrækkelige data om brugen af KINZALMONO hos gravide kvinder.
There are no adequate data from the use of Kinzalmono in pregnant women.
5. 3).
(See also section 5.3).
Hvis angiotensin II - receptorantagonister har været anvendt efter start af andet trimester, bør nyrefunktionen og kraniet kontrolleres ved hjælp af ultralyd.
Should exposure to angiotensin II receptor antagonists have occurred from the second trimester of pregnancy, ultrasound check of renal function and skull is recommended.
Telmisartan er kontraindiceret ved amning, da det ikke vides, om telmisartan udskilles i modermælk.
Telmisartan is contraindicated during lactation since it is not known whether it is excreted in human milk.
Man bør dog være opmærksom på, at der ved antihypertensiv behandling lejlighedsvis kan forekomme svimmelhed eller døsighed.
However, when driving vehicles or operating machinery it should be taken into account that dizziness or drowsiness may occasionally occur when taking antihypertensive therapy.
I placebokontrollerede forsøg var den samlede forekomst af bivirkninger ved brug af telmisartan, (41, 4%) sædvanligvis sammenlignelig med placebo (43, 9%).
The overall incidence of adverse events reported with telmisartan (41.4%) was usually comparable to placebo (43.9%) in placebo controlled trials.
Hyppigheden af bivirkninger var ikke dosisrelateret, og der var ingen korrelation med patienternes køn, alder eller race.
The incidence of adverse events was not dose related and showed no correlation with gender, age or race of the patients.
Bivirkningsreaktionerne vist nedenfor er indsamlet fra alle kliniske forsøg, der inkluderer 5788 hypertensive patienter behandlet med telmisartan.
The adverse drug reactions listed below have been accumulated from all clinical trials including 5788 hypertensive patients treated with telmisartan.
Meget almindelig (≥ 1/ 10); almindelig (≥ 1/ 100 til < 1/ 10); ikke almindelig (≥ 1/ 1. 000 til < 1/ 100); sjælden (≥ 1/ 10. 000 til < 1/ 1. 000); meget sjælden (< 1/ 10. 000), ikke kendt (kan ikke estimeres ud fra forhåndenværende data).
Adverse reactions have been ranked under headings of frequency using the following convention: very common (≥ 1/ 10); common (≥ 1/ 100 to < 1/ 10); uncommon (≥ 1/ 1,000 to < 1/ 100); rare (≥ 1/ 10,000 to < 1/ 1,000); very rare (< 1/ 10,000), not known (cannot be estimated from the available data.
Infektion i øvre luftveje herunder faryngitis og sinuitis Urinvejsinfektion herunder cystitis
Urinary tract infection including cystitis
Anæmi, thrombocytopeni Eosinofili
Eosinophilia
Synkope, insomni
Syncope, insomnia
Abnormal vision
Abnormal vision
Takykardi Bradykardi
Tachycardia Bradycardia
Abdominalsmerter, diare, tør mund, dyspepsi, flatulens Gastrointestinalt ubehag, opkastninger
Abdominal pain, diarrhoea, dry mouth, dyspepsia, flatulence Stomach upset, vomiting
Abnormal leverfunktion / - lidelse
Hepatic function abnormal/ liver disorder
Hyperhidrosis, pruritus Eksem, angioødem, urticaria Medikamentalt udløst allergisk udslæt, eksem
Hyperhidrosis, pruritus Erythema, angioedema, urticaria Drug eruption, toxic skin eruption, rash, eczema
Knogler, led, muskler og bindevæv Ikke almindelig: Myalgi
Muscoloskeletal and connective tissue disorders
Artralgi, rygsmerter (f. eks. iskias), muskelkramper eller smerter i ekstremiteter, kraftesløshed
Myalgia Arthralgia, back pain (e. g. sciatica), muscle cramps, pain in limb, weakness
Tendonitis
Tendonitis
Nyrer
Renal and urinary disorders
Nedsat nyrefunktion herunder akut nyresvigt
Renal impairment including acute renal failure
Brystsmerter, Influenzalignende symptomer Manglende virkning af lægemidlet
Influenza-like illness Drug ineffective
7 Laboratorieundesøgelser
Investigations
Forhøjet urinsyre, forhøjet kreatinin, forhøjede leverenzymer, forhøjet kreatinin- fosfokinase
Blood uric acid increased, blood creatinine increased, hepatic enzyme increased, blood creatine phosphokinase increased
Provokeret opkastning og/ eller maveudskylning er mulige behandlinger.
Suggested measures include induction of emesis and / or gastric lavage.
Ved hypotension skal patienten lægges i rygleje, og der skal hurtigt gives salt - og væskesubstitution.
If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacement given quickly.
Angiotensin II- antagonister, almindelige, ATC kode:
Angiotensin II Antagonists, plain, ATC Code:
Telmisartan er en oralt administreret aktiv specifik angiotensin II- receptorsubtype 1 (AT1) - antagonist.
Telmisartan is an orally active and specific angiotensin II receptor (type AT1) antagonist.
Telmisartan displacerer angiotensin II med meget høj affinitet fra dets bindingssted på AT1 - receptorsubtypen, som er ansvarlig for de kendte virkninger af angiotensin II.
Telmisartan displaces angiotensin II with very high affinity from its binding site at the AT1 receptor subtype, which is responsible for the known actions of angiotensin II.
Telmisartan hæmmer ikke “ angiotensin- converting - enzyme ” (kininase- II enzymet), som også nedbryder bradykinin.
Telmisartan does not inhibit angiotensin converting enzyme (kininase II), the enzyme which also degrades bradykinin.
En dosis på 80 mg telmisartan givet til raske frivillige hæmmer næsten fuldstændigt en angiotensin II - provokeret blodtryksforhøjelse.
In human, an 80 mg dose of telmisartan almost completely inhibits the angiotensin II evoked blood pressure increase.